Evaluating Technology and Its Application in the De-Escalation of Care

Wednesday, April 29, 2020

1:00 PM-5:00 PM

COURSE MODERATORS: Richard Fine, MD; Julie Margenthaler, MD

FACULTY: Michael Berry, MD; Judy Boughey, MD; David Brenin, MD; Richard Fine, MD; Julie Margenthaler, MD; Rakesh Patel, MD

COURSE DESCRIPTION:
The management of breast disease and breast cancer is continually being influenced by emerging technology and data with a focus on reducing the extent of surgery, radiation and chemotherapy. In addition, the changing healthcare environment is influencing the adoption of these sometimes-helpful techniques and therapies. Surgeons need to evaluate and understand this evolving data and technologies to adequately determine their appropriate role and potentially provide a higher level of care and weigh these benefits against their economic impact to the patient, the healthcare facility and to rising healthcare costs.

With the implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), surgeons will participate in one of two quality payment systems; Merit-based Incentive Payment Systems (MIPS) or Alternative Payment Models (APM) focusing on cost savings and quality improvements. Episodes of care are here and will be used to reimburse systems. There will be one fee per each breast cancer patient regardless of the approach to the patient or the technologic advances being implemented.

The course will focus on the pros and cons of alternatives to lumpectomy and alternatives to post-surgical therapy. The course will explore the current state of ablative technologies for non-surgical treatment of breast cancer in select patients. In breast conservation we have moved from 6 weeks of whole breast radiation to accelerated therapy options which include the Canadian regimen, APBI and IORT to select patients not needing radiation therapy. Lastly, we have numerous genomic profiling options to help determine which patients will benefit not only with chemotherapy but radiation therapy (especially in DCIS) as well.

A significant amount of time will be dedicated to a critical review of the published data and the cost-effectiveness of therapies & technology. The participant should complete the course better equipped to determine the need for these technologies in their practice or center. This will be accomplished through a didactic format built around faculty lecture, case presentation, debate and interactive attendee participation.

COURSE OBJECTIVES:
This course will offer participants an opportunity to become familiar, through didactic lectures, case presentations and panel with the following:

- Nonsurgical therapy with ablative technology
- Options and practical aspects of accelerated breast radiation, Canadian regimen, 3D conformal, balloon and strut based APBI
- Program development in partial breast radiation/IORT
- The potential for omitting radiation in select patients
- The current state of the art in genomic profiling for determining the benefit of adjuvant and neo-adjuvant chemotherapy
- The current state of the art in genomic profiling for determining the benefit of radiation in patients with DCIS
- Consider how genomic profiling may assist with decisions about radiation or axillary dissection of the positive axilla after neoadjuvant chemotherapy.
- How the changing healthcare reimbursement landscape will affect radiation practice

CME Information: The American Society of Breast Surgeons designates this live activity for a maximum of 3.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Evaluating Technology and Its Application in the De-Escalation of Care

Wednesday, April 29, 2020

PRELIMINARY AGENDA

1:00 PM -1:05 PM	Introductions and Overview of Course	Richard Fine, MD
	Alternatives to Lumpectomy: Ablative Therapies	
	Patient Selection, Current Data and the Economics Compared to Surgery	
1:05 PM -1:25 PM	Cryotherapy	Richard Fine, MD
1:25 PM -1:45 PM	Laser, Radiofrequency Ablation	David Brenin, MD
	Alternatives to Whole Breast Radiation Therapy	
	Is Six Weeks of Whole Breast Radiation Gone? Examining Accelerated Radiation Platforms	
1:45 PM -2:10 PM	Accelerated Partial Breast Radiation: Do we Give 3-4 Weeks of WBR, Balloon or Strut-Based 5-day APBI, or 3D Conformal External Beam APBI?	Julie Margenthaler, MD
2:10 PM -2:30 PM	Intraoperative Radiation Therapy: Why has IORT not Been Widely Accepted? From Data to Logistics of Program Development	Rakesh Patel, MD
2:30 PM -2:45 PM	Omitting Radiation Therapy Altogether	Rakesh Patel, MD
2:45 PM -3:00 PM	The Economics of Radiation Therapy: Will Changes in Healthcare Reimbursement Change Recommendations?	Rakesh Patel, MD
3:00 PM -3:15 PM	Break	
	Molecular Diagnostic Tools in De-Escalation of Care	
3:15 PM -3:40 PM	Molecular Diagnostic Tools for De-Escalation of Chemotherapy: Deciphering the Options; Prognostics vs. Predictive. Can They Help with Axillary Management Decision After Neoadjuvant Chemotherapy?	Judy Boughey, MD
3:40 PM -4:00 PM	Molecular Diagnostic Tools for De-Escalation of Radiation: Can Some DCIS Patients Avoid Radiation?	Michael Berry, MD
4:00 PM -5:00 PM	Case-Based Panel Discussion	Richard Fine, MD Julie Margenthaler, MD All Faculty
5:00 PM	Adjourn	